The global acute myeloid Leukemia treatment market is expected to grow at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2023-2031. The increasing prevalence of AML and the development of new therapies are the primary drivers of market growth.
The exact cause of AML is unknown, but risk factors include exposure to certain chemicals, radiation, and genetic disorders. Symptoms of AML include fatigue, weakness, shortness of breath, easy bruising or bleeding, fever, and infections. Treatment options for AML include chemotherapy, targeted therapy, and stem cell transplantation. The choice of treatment depends on factors such as the patient's age, overall health, and the type and stage of AML. Early diagnosis and treatment are essential for a better prognosis in patients with AML.
The exact prevalence of AML is difficult to determine, as the disease is often misdiagnosed or underdiagnosed. However, it is estimated that there are approximately 20,000 new cases of AML diagnosed each year in the United States, with a slightly higher incidence in men than in women. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of developing AML. Exposure to certain chemicals, such as benzene, and radiation are also known risk factors for the development of AML.
Chemotherapy is currently the most common form of treatment for AML, accounting for over 50% of the market share in 2021. However, targeted therapy, which includes drugs such as venetoclax and midostaurin, is expected to grow at a faster rate during the forecast period. Targeted therapy is more specific and less toxic than chemotherapy, making it an attractive option for patients with AML.
North America dominates the AML treatment market, accounting for over 40% of the global market share. The presence of a well-established healthcare infrastructure and a high prevalence of AML in the region is driving market growth. Europe is the second-largest market for AML treatment, with the growing adoption of novel therapies and the increasing focus on precision medicine driving market growth.
The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing prevalence of AML in the region and the rising healthcare expenditure. The growing awareness about AML and the availability of new treatment options are also expected to contribute to market growth.
Acute Myeloid Leukemia Treatment Market: Introduction
Acute myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells, which can interfere with the production of normal blood cells in the bone marrow. AML is a serious and life-threatening disease that can spread quickly to other parts of the body if not treated promptly.The exact cause of AML is unknown, but risk factors include exposure to certain chemicals, radiation, and genetic disorders. Symptoms of AML include fatigue, weakness, shortness of breath, easy bruising or bleeding, fever, and infections. Treatment options for AML include chemotherapy, targeted therapy, and stem cell transplantation. The choice of treatment depends on factors such as the patient's age, overall health, and the type and stage of AML. Early diagnosis and treatment are essential for a better prognosis in patients with AML.
Acute Myeloid Leukemia Epidemiology
Acute Myeloid Leukemia (AML) is a relatively rare disease, but it is the most common type of acute Leukemia in adults. The incidence of AML increases with age, and the disease is more commonly diagnosed in people over the age of 60. AML affects men and women equally, and there is no significant difference in the incidence of AML between different racial or ethnic groups.The exact prevalence of AML is difficult to determine, as the disease is often misdiagnosed or underdiagnosed. However, it is estimated that there are approximately 20,000 new cases of AML diagnosed each year in the United States, with a slightly higher incidence in men than in women. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of developing AML. Exposure to certain chemicals, such as benzene, and radiation are also known risk factors for the development of AML.
Acute Myeloid Leukemia Treatment Market Segmentations
The market can be categorised into diagnosis method, therapy type, and treatment channel.Market Breakup by Diagnosis Methods
- Biopsy and Bone Marrow Aspiration
- Complete Blood Count and Differential
- Philadelphia Chromosome Presence
- Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
- Immunophenotyping or Phenotyping by Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Others
Market Breakup by Therapy Type
- Targeted Drugs
- Chemotherapy
- Stem/Bone Marrow Treatment
- Radiation Therapy
- Others
Market Breakup by Treatment Channel
- Public
- Private
Acute Myeloid Leukemia Treatment Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Acute Myeloid Leukemia Treatment Market Scenario
The global acute myeloid Leukemia (AML) treatment market is expected to witness significant growth in the coming years. The market is driven by the increasing prevalence of AML and the development of new therapies.Chemotherapy is currently the most common form of treatment for AML, accounting for over 50% of the market share in 2021. However, targeted therapy, which includes drugs such as venetoclax and midostaurin, is expected to grow at a faster rate during the forecast period. Targeted therapy is more specific and less toxic than chemotherapy, making it an attractive option for patients with AML.
North America dominates the AML treatment market, accounting for over 40% of the global market share. The presence of a well-established healthcare infrastructure and a high prevalence of AML in the region is driving market growth. Europe is the second-largest market for AML treatment, with the growing adoption of novel therapies and the increasing focus on precision medicine driving market growth.
The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing prevalence of AML in the region and the rising healthcare expenditure. The growing awareness about AML and the availability of new treatment options are also expected to contribute to market growth.
Key Players in the Global Acute Myeloid Leukemia Treatment Market
The report gives an in-depth analysis of the key players involved in the acute myeloid Leukemia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd
- Sanofi S.A
- Pfizer Inc
- Oncolyze Inc
- Syndax Pharmaceuticals Inc
- AbbVie Inc
- Amgen Inc
- Servier Pharmaceutical LLC
- F. Hoffmann-La Roche Ltd
- Viracta Therapeutics, Inc
- Novartis AG
- Otsuka Holdings Co. Ltd
Table of Contents
1 Preface
4 Acute Myeloid Leukemia Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Needs
8 Global Acute Myeloid Leukemia Treatment Market
9 North America Acute Myeloid Leukemia Treatment Market
10 Europe Acute Myeloid Leukemia Treatment Market
11 Asia Pacific Acute Myeloid Leukemia Treatment Market
12 Latin America Acute Myeloid Leukemia Treatment Market
13 Middle East and Africa Acute Myeloid Leukemia Treatment Market
14 Acute Myeloid Leukemia Treatment Market Dynamics
15 Supplier Landscape
16 Global Acute Myeloid Leukemia Treatment Market- Drug Distribution Model (Additional Insight)
17 Payment Methods (Additional Insight)
Companies Mentioned
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- Oncolyze Inc.
- Syndax Pharmaceuticals Inc.
- AbbVie Inc.
- Amgen Inc.
- Servier Pharmaceutical LLC
- F. Hoffmann-La Roche Ltd
- Viracta Therapeutics, Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd
Methodology
LOADING...
Related Reports
Relapsed/refractory acute myeloid leukemia (AML) - Pipeline Insight, 2024
- Clinical Trials
- 180 Pages
- Global
From
From
Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report
- Report
- 356 Pages
- Global
From
Acute myeloid leukaemia - Pipeline Insight, 2024
- Clinical Trials
- 230 Pages
- Global
From
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
